Hoth Therapeutics, Inc. (HOTH) Tuesday announced positive preclinical results for HT-KIT, a novel targeted therapy for gastrointestinal stromal tumors (GIST).
GIST is a rare but aggressive cancer often driven by activating mutations in the KIT receptor. Results from the study showed that HT-KIT effectively reduced KIT receptor expression within 24 hours, with effects sustained for 72 hours. Further, HT-KIT triggered significant tumor cell death as early as 24 hours post-treatment.
"By directly targeting the underlying genetic drivers of GIST, HT-KIT has the potential to overcome limitations of existing therapies and provide a new therapeutic strategy for patients with KIT-driven malignancies," said Robb Knie, CEO of Hoth Therapeutics.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.